EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today ...

Learn how caffeine affects Parkinson's disease prevention and treatment. New research uncovers both protective benefits and ...

Vasoactive Intestinal Peptide (VIP) is an intriguing neuropeptide with a wide range of potential biological impacts, ...

Construction of the experimental model based on neurite outgrowth and neuroprotection for evaluating the effects of natural products and high-throughput screening of active compounds. Please note: The ...

To explore the possibility that the excitatory amino acid glutamate might be associated with the disease process of glaucoma, which is characterized by the death of retinal ganglion cell neurons and ...

Glaucoma, the second leading cause of blindness globally, affects millions and is projected to reach 111.8 million cases by ...

On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 – ...

Electrical stimulation therapy is being explored as a potential treatment to enhance neuroplasticity and improve visual ...

Department of Geriatric Medicine, University of Birmingham, Clinical Investigation Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK Department of Clinical Pharmacology, University of ...

Blogging Stroke highlights high-impact studies published in the journal Stroke. In addition to article summaries, Blogging Stroke includes interviews with authors of recently published Stroke articles ...

Myristamide enhances cognitive function and BDNF in mice, indicating Camembert cheese's potential in combating cognitive ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...